# 5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)

> **NCT04610372** · NA · RECRUITING · sponsor: **British Columbia Cancer Agency** · enrollment: 168 (estimated)

## Conditions studied

- Oligometastatic Prostate Cancer

## Interventions

- **RADIATION:** Hypofractionated external beam radiotherapy
- **RADIATION:** High dose rate brachytherapy
- **RADIATION:** Permanent seed implant
- **RADIATION:** Stereotactic body radiotherapy

## Key facts

- **NCT ID:** NCT04610372
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-12
- **Primary completion:** 2030-06-30
- **Final completion:** 2033-06-30
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04610372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04610372, "5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT04610372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*